GLOBUS MEDICAL (GMED) Company Report

Globus Medical reported Q3 2025 sales of $769 million, an increase of 22.9% over the prior year quarter, with legacy Globus contributing $669.8 million and the recently acquired Nevro business adding $99.3 million.
Non-GAAP diluted earnings per share grew 42.6% to $1.18, and the company generated a record Q3 free cash flow of $213.9 million.
Consolidated adjusted EBITDA margin was 32.8%, with legacy Globus achieving 35.3% and the Nevro business reaching a positive 16.2%.
The company raised its full-year 2025 net sales guidance to a range of $2.86 billion - $2.9 billion and its non-GAAP diluted EPS guidance to between $3.75 and $3.85.
Globus Medical repurchased $40 million of shares during Q3 2025, bringing year-to-date repurchases to $256 million, with $435 million remaining under the share repurchase program authorization as of September 30, 2025.

Nov 6, 2025, 9:30 PM

Transcript

Globus Medical Reports Strong Third Quarter 2025 Results and Raises Full-Year Guidance

GMED

Earnings

Guidance Update

Share Buyback

Globus Medical reported worldwide net sales of $769.0 million for the third quarter of 2025, representing a 22.9% increase over the third quarter of 2024.
Non-GAAP diluted earnings per share (EPS) for Q3 2025 was $1.18, an increase of 42.6% compared to the prior year quarter.
The company achieved record non-GAAP free cash flow of $213.9 million in Q3 2025, up 24% quarter-over-quarter.
Globus Medical executed share repurchases of $40 million in Q3 2025, bringing total repurchases to $255.5 million through the first nine months of 2025.
The company increased its full-year 2025 revenue guidance to a range of $2.86 billion to $2.90 billion and its non-GAAP fully diluted EPS guidance to a range of $3.75 to $3.85.

Nov 6, 2025, 9:25 PM

8-K

Globus Medical Reports Third Quarter 2025 Results and Raises Full-Year Guidance

GMED

Earnings

Guidance Update

Share Buyback

Globus Medical reported worldwide net sales of $769.0 million for the third quarter ended September 30, 2025, marking a 22.9% increase over the prior year, with the recently acquired Nevro business contributing $99.3 million.
GAAP diluted earnings per share (EPS) was $0.88, an increase of 134.0%, and non-GAAP diluted EPS was $1.18, up 42.6% compared to the third quarter of 2024.
The company achieved record non-GAAP free cash flow of $213.9 million in Q3 2025 and executed $40 million in share repurchases during the quarter, bringing total repurchases to $255.5 million through the first nine months of 2025.
Globus Medical increased its full-year 2025 guidance, with revenue now expected to be in the range of $2.86 to $2.90 billion and non-GAAP fully diluted EPS in the range of $3.75 to $3.85.

Nov 6, 2025, 9:15 PM

Press Release

Globus Medical Announces Leadership Transitions and Preliminary Q2 2025 Sales Results

GMED

CEO Change

CFO Change

Guidance Update

Globus Medical announced Keith Pfeil has been appointed President and Chief Executive Officer, effective July 18, 2025, succeeding Daniel Scavilla, and Kyle Kline has been appointed Senior Vice President and Chief Financial Officer.
The company anticipates preliminary second quarter 2025 sales to be approximately $745.3 million, an 18.4% as-reported increase over the second quarter of 2024.
Globus Medical reaffirmed its full-year 2025 guidance for revenue to be in the range of $2.80 to $2.90 billion and non-GAAP fully diluted earnings per share to be in the range of $3.00 to $3.30.

Jul 21, 2025, 12:00 PM

Press Release

Globus Medical Approves Equity Incentive Plan Amendment and Board Elections

GMED

Proxy Vote Outcomes

Executive Compensation

Board Change

Amendment to the 2021 Equity Incentive Plan approved at the Annual Meeting on June 4, 2025, becoming effective immediately upon stockholder approval.
New Board directors elected with detailed voting results confirming the appointment of several candidates.
Advisory vote on executive compensation was approved, establishing annual reviews until 2031.

Jun 5, 2025, 12:00 AM

8-K

Globus Medical Initiates $500 Million Share Repurchase Program

GMED

Share Buyback

Globus Medical Inc. announced a board-approved share repurchase program of up to $500 million targeting its Class A common stock on May 15, 2025.
The repurchase will be executed at management’s discretion, considering varying market conditions and general business factors.

May 15, 2025, 12:00 AM

8-K

Globus Medical Reports Q1 2025 Results

GMED

Earnings

Guidance Update

Worldwide net sales reached $598.1 million in Q1 2025, reflecting a 1.4% decline overall, with U.S. net sales modestly up by 0.2% and international net sales down by 7.7%.
GAAP net income improved to $75.5 million with diluted EPS at $0.54, marking a significant turnaround from a loss in Q1 2024.
The company achieved a debt-free status by fully repaying the remaining $450 million from the NuVasive merger, and delivered record Q1 free cash flow.

May 8, 2025, 12:00 AM

8-K

Globus Medical Completes Acquisition of Nevro Corp

GMED

M&A

Globus Medical completed its acquisition of Nevro Corp, integrating Nevro as a wholly owned subsidiary and expanding its portfolio in musculoskeletal and neuromodulation technologies.
The merger involved converting each Nevro share into $5.85 in cash, effectively finalizing the deal on April 3, 2025.
The strategic acquisition aims to unlock a $2 billion market opportunity and enhance Globus Medical’s market presence.

Apr 3, 2025, 12:00 AM

8-K

Globus Medical Updates Post-NuVasive Merger and Nevro Acquisition Strategy

GMED

M&A

Product Launch

New Projects/Investments

Integration progress: The company highlighted its successful merger with NuVasive, which doubled its reach by combining complementary spine technologies and expanded its access to both domestic and international markets.
Acquisition strategy: Globus Medical announced its intent to acquire Nevro, a move aimed at entering the spinal cord stimulation market—a new, nearly $2 billion market opportunity that supports diversified revenue streams.
Pipeline and product innovations: The call reviewed new product developments including the DuraPro oscillating drill, enhanced capabilities in the Excelsius robotic system, and the FDA-cleared Reline system, all designed to offer a competitive technical edge.
Cost synergies and capital allocation: The company underscored its progress in executing cost-saving synergies—reporting over $94 million achieved in the first full year—with plans to reinvest cash flow into R&D, manufacturing, and strategic M&A opportunities.

Mar 10, 2025, 11:31 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for GLOBUS MEDICAL.